- Conditions
- Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Interventions
- Nemvaleukin and Pembrolizumab Combination, Pembrolizumab, Nemvaleukin, Pegylated Liposomal Doxorubicin (PLD), Paclitaxel, Topotecan, Gemcitabine
- Biological · Drug
- Lead sponsor
- Mural Oncology, Inc
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 456 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 31 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1369–1392
of 6,316
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Migraine
- Interventions
- Elismetrep, Placebo
- Drug
- Lead sponsor
- TriGemX Bio, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 113
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 93 more
- Conditions
- Migraine, Chronic Headache
- Interventions
- Topiramate
- Drug
- Lead sponsor
- Emerald City Headache Organization
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Pneumothorax
- Interventions
- Primary Surgery Group, Initial Non-operative management
- Procedure
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 5 Years to 18 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Sjogren's Syndrome
- Interventions
- tofacitinib, Placebo
- Drug · Other
- Lead sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Turner Syndrome, Primary Ovarian Insufficiency
- Interventions
- Estradiol transdermal patch 0.025mg/24 hours- 1/8th fractionated patch
- Drug
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 8 Years to 12 Years · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Glaucoma Open-Angle Primary, Ocular Hypertension
- Interventions
- H-1337 1.0%
- Drug
- Lead sponsor
- D. Western Therapeutics Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- 3'-deoxy-3'-[18F]fluorothymidine
- Device
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2027
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Primary Hyperparathyroidism, Parathyroid Cancer, Multiple Endocrine Neoplasias, Heritable Hyperparathyroidism, Hyperparathyroid-jaw Tumor Syndrome
- Interventions
- 18F-FCH, NeuroEXPLORER
- Drug · Device
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 193 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2036
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- Not listed
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- HIV Infections
- Interventions
- Abacavir sulfate, Lamivudine, and Zidovudine, Lopinavir/Ritonavir
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 4
- States / cities
- Minneapolis, Minnesota • New York, New York • Cleveland, Ohio
- Conditions
- Ocular Hypertension, Glaucoma
- Interventions
- AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%, AGN-210669 ophthalmic solution, 0.025%, bimatoprost ophthalmic solution 0.03%, AGN-210669 vehicle ophthalmic solution
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Artesia, California
- Conditions
- Malignant Brain Neoplasm, Metastatic Malignant Neoplasm in the Brain, Recurrent Malignant Brain Neoplasm
- Interventions
- Dexamethasone
- Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Primary Brain Tumor
- Interventions
- Dotarem®, Gadovist®/Gadavist®
- Drug
- Lead sponsor
- Guerbet
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 279 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 11 more
- Conditions
- Migraine, Small Vessel Ischemic Disease, Multiple Sclerosis
- Interventions
- Brain Neuroimaging
- Diagnostic Test
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 20 Years to 59 Years · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Post-COVID-19 Syndrome, Postural Tachycardia Syndrome, Dysautonomia
- Interventions
- Non-invasive vagus nerve stimulation, Sham Intervention
- Device
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Migraine, Pain
- Interventions
- Nitrous Oxide
- Drug
- Lead sponsor
- Children's Hospitals and Clinics of Minnesota
- Other
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Primary Immunodeficiency
- Interventions
- Gadolinium For abdomen, Gadolinium For lower back, Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, Efficacy of Gammagard subcutaneously at Week 36, Efficacy of Gammagard subdermally at Week 36, Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, Adverse Reactions of Gammagard subcutaneously at Week 36, Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, Adverse Reactions of Gammagard subdermally at Week 36
- Drug
- Lead sponsor
- ASIS Corporation
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Westminster, California
- Conditions
- Migraine Disorders
- Interventions
- Emotional Awareness and Expression Therapy (EAET)
- Behavioral
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Alcohol Dependence, HIV/AIDS
- Interventions
- Clinician Guide (CG), Clinician Guide plus HealthCall
- Behavioral
- Lead sponsor
- Research Foundation for Mental Hygiene, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Primary Sjögren Syndrome
- Interventions
- RSLV-132, Placebo
- Drug
- Lead sponsor
- Resolve Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 24
- States / cities
- Chula Vista, California • Tustin, California • Boca Raton, Florida + 20 more
- Conditions
- Kidney Cancer, Liver Cancer
- Interventions
- hypoxia-activated prodrug TH-302, sorafenib tosylate
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Rochester, Minnesota
- Conditions
- Long QT Syndrome
- Interventions
- QTc Meter
- Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- Up to 5 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Non-Hodgkin Lymphoma, Lymphoma, Diffuse Large B-Cell Lymphoma, Gray-zone Lymphoma, Primary Central Nervous System Lymphoma
- Interventions
- Pembrolizumab
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland